CHI Podcasts

Prof. Matthew Lungren shares his stories on how he got to where he is now and where his artificial intelligent inspiration for medicine comes from. He also talks about many great collaborations at the Stanford Center in precision medicine and what he’s looking to see more in this field in the next 5 years.

For more information, please visit https://www.TriConference.com/Precision-Medicine

Gene therapy presents a promising path ahead for patients of rare diseases. The United States Food and Drug Administration’s Director of the Center for Biologics Evaluation and Research, Dr. Peter Marks discusses his work advancing production and availability of gene therapies for rare disorders, and the unique challenges to producing efficacious therapeutics in this field.

For more information, please visit https://www.TriConference.com/Gene-Therapy

Nancy Sajjadi, an independent bioassay quality consultant with over 30 years of experience in biopharmaceutical product development, discusses her history in the bioassay field and how her experience has fostered her passion for teaching biostatistics to non-statisticians with CHI.

Topics include: challenges in developing bioassays for cell & gene therapies, regulatory considerations and standards for bioassays, fostering collaboration between statisticians and bench scientists, and more

For more information, please visit https://www.ImmunogenicitySummit.com/Workshop

Prof. Joshua Krieger from Harvard Business School shares his perspectives on some of the challenges and opportunities in commercialization of diagnostic tests and gives us a preview of his business case study on Genomic Health.

For more information, please visit https://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics

Samuel Levy of Bluestar Genomics speaks to CHI on March 13, 2019. Dr. Levy will be speaking during The Liquid Biopsy Summit, June 17-19, in San Francisco, CA.

Topics include cell-free diagnostics in precision medicine, transformation & growth in the liquid biopsy field, epigenomic assays for cancer detection, and opportunities ahead.

For more information, please visit https://www.LiquidBiopsySummit.com/Programs

Dr. Konstantinos Mitsakakis explains the One Health approach, and how the pursuit benefits diverse avenues of diagnostic research.

For more information, please visit https://www.MolecularDXEurope.com/Point-of-Care-Dx

Dr. Richard Levenson discusses the role of AI in digital pathology – what works, and what needs to be done for AI to reach its full potential.

For more information, please visit https://www.TriConference.com/Digital-Pathology

Harry Glorikian interviews Niven R. Narain about his approach on how to add more precision to the process of drug development and diagnostic development while engage more reproducibility. Niven also discusses how to use the biomarkers not only as a readout but as a vehicle and an agent to design clinical trials much differently.

For more information, please visit https://www.TriConference.com/Precision-Medicine

Dr. Mark Stewart discusses the role of the tumor mutational burden (TMB) in cancer research and the need for harmonization throughout the process.

For more information, please visit https://www.triconference.com/Companion-Diagnostics

Dr. Jennifer Chadwick shares her journey from academia to industry, and the best advice that got her to where she is today.